These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 8996219

  • 1. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats.
    Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):384-92. PubMed ID: 8996219
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist.
    Sacaan AI, Reid RT, Santori EM, Adams P, Correa LD, Mahaffy LS, Bleicher L, Cosford ND, Stauderman KA, McDonald IA, Rao TS, Lloyd GK.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):373-83. PubMed ID: 8996218
    [Abstract] [Full Text] [Related]

  • 3. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist.
    Rao TS, Adams PB, Correa LD, Santori EM, Sacaan AI, Reid RT, Cosford ND.
    Brain Res; 2008 Oct 09; 1234():16-24. PubMed ID: 18692487
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological characterization of SIB-1663, a conformationally rigid analog of nicotine.
    Rao TS, Sacaan AI, Menzaghi FM, Reid RT, Adams PB, Correa LD, Whelan KT, Vernier JM.
    Brain Res; 2004 Apr 02; 1003(1-2):42-53. PubMed ID: 15019562
    [Abstract] [Full Text] [Related]

  • 6. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
    Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS.
    J Pharmacol Exp Ther; 1994 Jul 02; 270(1):310-8. PubMed ID: 7518514
    [Abstract] [Full Text] [Related]

  • 7. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors.
    Bontempi B, Whelan KT, Risbrough VB, Lloyd GK, Menzaghi F.
    Neuropsychopharmacology; 2003 Jul 02; 28(7):1235-46. PubMed ID: 12700710
    [Abstract] [Full Text] [Related]

  • 8. Epibatidine: a nicotinic acetylcholine receptor agonist releases monoaminergic neurotransmitters: in vitro and in vivo evidence in rats.
    Sacaan AI, Menzaghi F, Dunlop JL, Correa LD, Whelan KT, Lloyd GK.
    J Pharmacol Exp Ther; 1996 Feb 02; 276(2):509-15. PubMed ID: 8632316
    [Abstract] [Full Text] [Related]

  • 9. Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests.
    Andreasen JT, Olsen GM, Wiborg O, Redrobe JP.
    J Psychopharmacol; 2009 Sep 02; 23(7):797-804. PubMed ID: 18583432
    [Abstract] [Full Text] [Related]

  • 10. The alpha4beta2 agonist SIB 1765F, but not the alpha7 agonist AR-R 17779, cross-sensitises to the psychostimulant effects of nicotine.
    Grottick AJ, Wyler R, Higgins GA.
    Psychopharmacology (Berl); 2000 Jun 02; 150(2):233-6. PubMed ID: 10907678
    [Abstract] [Full Text] [Related]

  • 11. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT.
    J Pharmacol Exp Ther; 1994 Jul 02; 270(1):319-28. PubMed ID: 7913497
    [Abstract] [Full Text] [Related]

  • 12. Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands.
    Grottick AJ, Haman M, Wyler R, Higgins GA.
    Neuropsychopharmacology; 2003 May 02; 28(5):880-7. PubMed ID: 12637951
    [Abstract] [Full Text] [Related]

  • 13. Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice.
    Biala G, Staniak N.
    Pharmacol Biochem Behav; 2010 Aug 02; 96(2):141-7. PubMed ID: 20451547
    [Abstract] [Full Text] [Related]

  • 14. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.
    Schneider JS, Pope-Coleman A, Van Velson M, Menzaghi F, Lloyd GK.
    Mov Disord; 1998 Jul 02; 13(4):637-42. PubMed ID: 9686767
    [Abstract] [Full Text] [Related]

  • 15. Beta2-subunit-containing nicotinic acetylcholine receptors are critical for dopamine-dependent locomotor activation following repeated nicotine administration.
    King SL, Caldarone BJ, Picciotto MR.
    Neuropharmacology; 2004 Jul 02; 47 Suppl 1():132-9. PubMed ID: 15464132
    [Abstract] [Full Text] [Related]

  • 16. Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist.
    Damaj MI, Glassco W, Aceto MD, Martin BR.
    J Pharmacol Exp Ther; 1999 Oct 02; 291(1):390-8. PubMed ID: 10490929
    [Abstract] [Full Text] [Related]

  • 17. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex.
    Drew AE, Derbez AE, Werling LL.
    Synapse; 2000 Oct 02; 38(1):10-6. PubMed ID: 10941136
    [Abstract] [Full Text] [Related]

  • 18. Regulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways.
    Gopalakrishnan M, Molinari EJ, Sullivan JP.
    Mol Pharmacol; 1997 Sep 02; 52(3):524-34. PubMed ID: 9281615
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo.
    Sidhpura N, Redfern P, Rowley H, Heal D, Wonnacott S.
    Biochem Pharmacol; 2007 Oct 15; 74(8):1292-8. PubMed ID: 17678630
    [Abstract] [Full Text] [Related]

  • 20. Morphine-induced place preference: involvement of cholinergic receptors of the ventral tegmental area.
    Rezayof A, Nazari-Serenjeh F, Zarrindast MR, Sepehri H, Delphi L.
    Eur J Pharmacol; 2007 May 07; 562(1-2):92-102. PubMed ID: 17336285
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.